Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058

NCT ID: NCT04991194

Last Updated: 2021-08-05

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 61 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-10-12
• Study Completion Date: 2016-12-30

Brief Summary

the purpose of this study is to determine the effect of age on the Pharmacokinetics (PK) profile of BIA 5-1058 at steady state after multiple oral doses

Detailed Description

This was a single-centre, open-label, parallel group, non-randomised, two-part multiple dose 10-day study in healthy young and elderly male and female subjects. The study comprised a screening evaluation between 2 and 28 days before the first Investigational Medicinal Product (IMP) administration, a hospitalisation period of 15 days comprising a treatment period of 10 days, and a follow-up visit approximately 7 days after discharge.

Part 1: Subjects received 1200 mg of BIA 5-1058 once a day (od), in fasting conditions, for 10 days Part 2 : Subjects received 400 mg of BIA 5-1058 od, in fasting conditions, for 10 days.

Conditions

Pulmonary Arterial Hypertension

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BIA 5-1058 1200 mg (Part I)

Subjects received 1200 mg of BIA 5-1058 once a day (od), in fasting conditions, for 10 days

Group Type: EXPERIMENTAL

BIA 5-1058

Intervention Type: DRUG

Each subject was administered either 1200 mg (Part 1) or 400 mg (Part 2) BIA 5-1058 od for 10 days, in fasting conditions for 8 hours \[Day (D)2 to D9\] or 10 hours (D1 and D13), and remained fasted for 2 hours (D2 to D9) or 4 hours (D1 and D13) post-dose. The formulation was tablets 100 mg and the mode of administration was oral.

BIA 5-1058 400 mg (Part II)

Subjects received 400 mg of BIA 5-1058 od, in fasting conditions, for 10 days.

Group Type: EXPERIMENTAL

BIA 5-1058

Intervention Type: DRUG

Each subject was administered either 1200 mg (Part 1) or 400 mg (Part 2) BIA 5-1058 od for 10 days, in fasting conditions for 8 hours \[Day (D)2 to D9\] or 10 hours (D1 and D13), and remained fasted for 2 hours (D2 to D9) or 4 hours (D1 and D13) post-dose. The formulation was tablets 100 mg and the mode of administration was oral.

Interventions

BIA 5-1058

Each subject was administered either 1200 mg (Part 1) or 400 mg (Part 2) BIA 5-1058 od for 10 days, in fasting conditions for 8 hours \[Day (D)2 to D9\] or 10 hours (D1 and D13), and remained fasted for 2 hours (D2 to D9) or 4 hours (D1 and D13) post-dose. The formulation was tablets 100 mg and the mode of administration was oral.

Intervention Type: DRUG

Other Intervention Names

Zamicastat

Eligibility Criteria

Inclusion Criteria

All subjects (young and elderly):

1. A signed and dated informed consent form before any study-specific screening procedure was performed;

2. Healthy male and female subjects as determined by the Investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs and digital 12-lead electrocardiogram (ECG);

3. Non-smoker or ex-smokers for at least 3 months at screening;

4. BMI between 18 and 30 kg/m2, inclusive;

5. Negative tests for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus antibodies (HCV Ab) and anti-human immunodeficiency virus antibodies (HIV-1 and HIV-2 Ab) at screening;

6. Clinical laboratory test results clinically acceptable at screening and admission to the study;

7. Negative screen for alcohol and drugs of abuse at screening and admission to the study;

If male:

8. Using an effective method of contraception with a pregnant partner or partner of childbearing potential (condom or occlusive cap [diaphragm or cervical or vault caps] with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomy) throughout the study;

9. Refraining from donating sperm throughout the study.

Young subjects only:

10. Males and females aged between 18 and 40 years, inclusive.

If female:

11. No childbearing potential by reason of surgery or at least 1 year post-menopause (i.e., 12 months post last menstrual period), or menopause confirmed by follicle-stimulating hormone (FSH) testing;

12. If of childbearing potential, using an effective non-hormonal method of contraception [intrauterine device or intrauterine system; condom or occlusive cap (diaphragm or cervical or vault caps) with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomized male partner, provided that he is the sole partner of that subject] for all the duration of the study;

13. If of childbearing potential, negative serum pregnancy test at screening and negative urine pregnancy test on admission to the study.

Elderly subjects only:

14. Males and females older than 65 years, inclusive.

Exclusion Criteria

All subjects (young and elderly):

1. Clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders;

2. Clinically relevant surgical history;

3. History of relevant atopy or drug hypersensitivity;

4. History of alcoholism or drug abuse;

5. Consumption of more than 14 units of alcohol a week [1 unit corresponds to 1 glass of 12° wine (10 cL), 1 glass of 45° pastis (2.5 cL), 1 glass of 40° whisky (2.5 cL), 1 glass of 12° champagne (10 cL), 1 glass of 18°aperitif drink (7 cL) or one 25-cL glass of 5°beer];

6. Significant infection or known inflammatory process at screening or admission to study;

7. Acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to the study;

8. Previous use of BIA 5-1058;

9. Use of any investigational drug or participation in any clinical trial within 90 days prior to screening;

10. Participation in more than 2 clinical trials within the 12 months prior to screening;

11. Donation or reception of any blood or blood products within the 3 months prior to screening;

12. Vegetarians, vegans or other medical dietary restrictions;

13. Not able to communicate reliably with the Investigator;

14. Unlikely to co-operate with the requirements of the study.

If male:

15. Not using an accepted effective method of contraception;

16. Refusing to refrain from donating sperm throughout the study.

Young subjects only:

17. Use of medicines within 2 weeks of admission that could affect the safety or other study assessments, in the Investigator's opinion;

If female of childbearing potential:

18. Pregnant or breastfeeding;

19. Not using an accepted effective contraceptive method or using oral contraceptives.

Elderly subjects only:

20. For elderly subjects, previously prescribed medications that interfered with absorption, distribution, metabolism, and excretion or safety/tolerability evaluation of BIA 5-1058 and adrenal or renal function were prohibited; however, previously prescribed medications that did not interfere with absorption, distribution, metabolism, and excretion or safety/tolerability evaluation of BIA 5-1058, adrenal or renal function and which could not interfere with the objectives of the study were allowed if the dose regimen had been stable for at least 4 weeks and was expected to remain stable throughout the study. Such concomitant medications were to be reviewed and mutually agreed upon by the Sponsor and the Investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Bial - Portela C S.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

2015-003682-28

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

BIA-51058-105

Identifier Type: -

Identifier Source: org_study_id